Blueprint Medicines' GAAP loss for 2021 was $644.085 million, compared to a profit of $313.882 million in the previous year. Revenue decreased 77.3% to $180.08 million from $793.735 million a year earlier.
Blueprint Medicines' GAAP loss for 2021 was $644.085 million, compared to a profit of $313.882 million in the previous year. Revenue decreased 77.3% to $180.08 million from $793.735 million a year earlier. 
ir.blueprintmedicines.com
English (US) 